Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer

医学 肺癌 化疗 程序性细胞死亡 程序性细胞死亡1 荟萃分析 肿瘤科 癌症 细胞凋亡 内科学 PD-L1 免疫疗法 生物化学 化学
作者
Hakan Bozcuk,Mehmet Artaç,Hasan Mutlu,Özlem Nuray Sever,Mustafa Yıldırım
出处
期刊:Journal of Oncology Pharmacy Practice [SAGE Publishing]
卷期号:27 (2): 405-413 被引量:3
标识
DOI:10.1177/1078155220964903
摘要

Background Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and this paper is designed to answer these clinical questions. Methods For this Meta-analysis, we searched PubMed, Science of Web, “Clinicaltrials.gov” and online sources for trials comparing PD-1 and PDL-1 CPIs in advanced NSCLC. The data for Hazard Ratio (HR) and their Confidence Intervals (CI) for Overall Survival (OS) was extracted. Results A sum of 9739 patients from 16 trials were included in the efficacy evaluation. For the OS endpoint, both PD-1 inhibitors (HR = 0.76, 95%CI = 0.69–0.83, P < 0.001) and PDL-1 inhibitors (HR = 0.84, 95%CI = 0.74–0.95, P < 0.001) were superior to chemotherapy in treatment naïve (upfront) patients, the results were similar in treatment refractory patients (PD-1 inhibitors (HR = 0.67, 95%CI = 0.60–0.75, P < 0.001) and PDL-1 inhibitors (HR = 0.78, 95%CI = 0.69–0.88, P < 0.001) were superior to chemotherapy). There was no difference in the effect of PD-1 and PDL-1 classes of CPIs over chemotherapy in treatment naïve and treatment refractory settings (Q = 1.88, df = 1, P = 0.017, and, Q = 3.27, df = 1, P = 0.070, respectively). Conclusion Efficacy of PD-1 and PDL-1 class of CPIs was not different, although differences among individual CPIs or their combinations cannot be excluded. We were also able to compute pooled efficacy data, as compared to chemotherapy alone, for trials where these groups of CPIs were utilized.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
量子星尘发布了新的文献求助10
1秒前
孙君健完成签到,获得积分10
2秒前
阳阳发布了新的文献求助10
2秒前
3秒前
yu完成签到,获得积分10
3秒前
Moshiqi发布了新的文献求助10
3秒前
orixero应助花开城北采纳,获得10
3秒前
欣欣发布了新的文献求助10
4秒前
SciGPT应助时遇采纳,获得10
4秒前
555557应助小李采纳,获得10
4秒前
小清新完成签到,获得积分10
5秒前
搜集达人应助樱悼柳雪采纳,获得10
5秒前
周周发布了新的文献求助10
5秒前
QQ完成签到,获得积分10
5秒前
碧蓝皮卡丘完成签到,获得积分10
6秒前
ylq发布了新的文献求助10
7秒前
人福药业完成签到,获得积分10
7秒前
dora完成签到,获得积分10
7秒前
Owen应助mia采纳,获得10
7秒前
天天快乐应助nkmenghan采纳,获得10
9秒前
乐乐应助CCCr采纳,获得10
9秒前
希望天下0贩的0应助wjx采纳,获得30
9秒前
上官若男应助周周采纳,获得10
10秒前
10秒前
10秒前
柔弱的马里奥完成签到,获得积分10
10秒前
爱听歌蘑菇完成签到,获得积分10
11秒前
11秒前
BL发布了新的文献求助10
13秒前
田様应助慕容松采纳,获得10
14秒前
李红玉发布了新的文献求助10
14秒前
panda发布了新的文献求助10
14秒前
金雪完成签到,获得积分10
14秒前
15秒前
CipherSage应助butter采纳,获得10
15秒前
16秒前
田様应助伶俐一曲采纳,获得10
16秒前
FashionBoy应助Monika采纳,获得10
16秒前
Zww发布了新的文献求助10
16秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219